Loading...
Market
How will Patanjali respond to regulatory actions regarding the 14 halted medicines by December 31, 2024?
2
Patanjali Ayurved Ltd•Ramdev•Supreme Court•Indian Medical Association•Hima Kohli•Sandeep Mehta•Patanjali•Uttarakhand State Licensing Authority
Resolution / Starting Odds
Resumes sale with modifications • 25%
Permanently halts sale • 25%
Appeals regulatory actions • 25%
Introduces new products • 25%
Official announcements from Patanjali Ayurved Ltd or regulatory updates
Story
Patanjali Halts Sale of 14 Medicines Amid Supreme Court Case Over Misleading Ads on July 9
Jul 9, 2024, 08:27 AM
Patanjali Ayurved Ltd, led by Ramdev, has halted the sale of 14 ayurvedic medicines following a Supreme Court case filed by the Indian Medical Association against the company for publishing misleading medical advertisements. The Supreme Court, with a bench presided by Justices Hima Kohli and Sandeep Mehta, heard the case on July 9. Patanjali informed the court that it has issued instructions to its 5,606 franchise stores to withdraw the suspended products. The Uttarakhand State Licensing Authority had suspended the manufacturing licenses for these products in April. Media platforms have been asked to stop broadcasting any related advertisements.
View original story
Similar markets
Yes • 50%
No • 50%
No new legal challenges • 25%
Fines imposed • 25%
Temporary ban on advertisements • 25%
Court-mandated corrective advertising • 25%
Yes • 50%
No • 50%
Fully compliant • 25%
Minor violations • 25%
Multiple violations • 25%
Major violations • 25%
Full Compliance • 33%
Partial Compliance • 33%
No Compliance • 33%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Fines • 25%
Imprisonment • 25%
Further Legal Actions • 25%
No Consequences • 25%
Significantly improved • 25%
Somewhat improved • 25%
No change • 25%
Worsened • 25%
No new launches • 25%
1-2 new launches • 25%
3-4 new launches • 25%
More than 4 new launches • 25%